The survival data from our Phase 2 tolerability trial on medicinal cannabis and high-grade gliomas, an aggressive brain tumour found that 47% (n=21) were still alive 2 1/2 years post-trial. This means that the participants were 5-7 years post diagnosis in a disease that has a 6–18-month survival rate. All but 2 of the participants were still taking an oral medicinal cannabis at night before bed. The dose was very low normally of a 1:1 THC to CBD combination. Hopefully more funding can be found to be able to conduct further research in this area.
- jschloss69